Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.768
+0.001 (0.09%)
At close: Nov 20, 2024, 4:00 PM
0.750
-0.018 (-2.36%)
After-hours: Nov 20, 2024, 4:59 PM EST
Invivyd Employees
As of December 31, 2023, Invivyd had 95 total employees, including 94 full-time and 1 part-time employees. The number of employees increased by 9 or 10.47% compared to the previous year.
Employees
95
Change (1Y)
9
Growth (1Y)
10.47%
Revenue / Employee
$121,726
Profits / Employee
-$2,369,853
Market Cap
91.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| FONAR | 561 |
| Harvard Bioscience | 416 |
| EDAP TMS | 307 |
| PetMed Express | 287 |
| Veru Inc. | 189 |
| Immunic | 77 |
| Regulus Therapeutics | 30 |
| Nuvectis Pharma | 13 |
IVVD News
- 6 days ago - Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 days ago - Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - GlobeNewsWire
- 8 days ago - Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively - GlobeNewsWire
- 14 days ago - Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 15 days ago - Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - GlobeNewsWire
- 23 days ago - Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability - GlobeNewsWire
- 23 days ago - Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants - GlobeNewsWire